We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Urine Proteome Analysis Approach Reduces Analysis Time and Enhances Identification Coverage

By LabMedica International staff writers
Posted on 19 Jun 2023

Urine serves as a promising source for early and sensitive biomarker discovery due to its non-invasive collection and ability to reflect accumulated changes within the human body. More...

However, analyzing the urine proteome poses challenges owing to its wide dynamic range, spanning approximately 10 orders of magnitude in protein concentrations. The presence of high-abundance proteins in urine can overshadow potential disease biomarkers to make their identification difficult. To address this issue, fractionation and depletion strategies are commonly employed prior to mass spectrometry (MS) analysis, aiming to improve the detection and identification of these elusive biomarkers. An alternative approach involves fractionating urine through ultracentrifugation (UC) to deplete high-abundance proteins, enabling the isolation of exosomes with high purity while retaining a majority of the high-abundance proteins in the supernatant. However, the strong centrifugal force during UC can unavoidably cause disruption in the intact structure of exosomes, leading to the isolation of minimal amounts from a small urine volume.

Researchers at the Chinese Academy of Sciences (Beijing, China) have now proposed an innovative solid-phase alkylation (SPA)-based sample preparation method that enables low-loss, anti-interference processing of sub-microgram proteomic samples. This new method combines UC fractionation, solid-phase extraction (SPA) sample preparation, and liquid chromatography-mass spectrometry (LC-MS), resulting in a comprehensive proteome profiling of urine known as CPU (comprehensive proteome profiling of urine). With this simple approach, the team successfully identified a total of 1,659 proteins using a short LC gradient of approximately one hour, which is 2.3 times more than the 730 proteins identified from raw urine without fractionation.

Significantly, in comparison to existing urine sample preparation methods, CPU offers notable advantages by not only significantly reducing analysis time by 3-4 times but also enhancing the identification coverage of the urine proteome by 130-160%. The researchers further applied this method in conjunction with label-free quantification to perform a comparative proteome analysis of urine samples from both IgA nephropathy (IgAN) patients and healthy donors. As a result, they identified 227 differentially expressed proteins, throwing light on potential biomarkers associated with IgAN. They found several members of the solute carrier family 22 (SLC22) to be up-regulated in IgAN patients, indicating a potential connection to the disruption of renal metabolic function in these individuals.

“Our results demonstrated that our developed method holds promise as a valuable tool for the discovery of disease-related biomarkers in urine," said lead author Xinxin Liu, a technician at Dalian Institute of Chemical Physics, Chinese Academy of Sciences.

Related Links:
Chinese Academy of Sciences 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
POC Immunoassay Analyzer
Procise DX
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.